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Background: Lower respiratory infections constitute a major disease burden worldwide. Treatment is usually
empiric and targeted towards typical bacterial pathogens. Understanding the prevalence of pathogens not cov-
ered by empirical treatment is important to improve diagnostic and treatment algorithms.
Methods: A prospective observational study in peri-urban communities of Yangon, Myanmar was conducted
between July 2018 and April 2019. Sputum specimens of 299 adults presenting with fever and productive
coughwere tested forMycobacterium tuberculosis (microscopy and GeneXpert MTB/RIF [Mycobacterium tubercu-
losis/resistance to rifampicin]) and Burkholderia pseudomallei (Active Melioidosis Detect Lateral Flow Assay and
culture). Nasopharyngeal swabs underwent respiratory virus (influenza A, B, respiratory syncytial virus) poly-
merase chain reaction testing.
Results: Among 299 patients, 32% (95% confidence interval [CI] 26 to 37) were diagnosed with tuberculosis
(TB), including 9 rifampicin-resistant cases. TB patients presented with a longer duration of fever (median 14 d)
and productive cough (median 30 d) than non-TB patients (median fever duration 6 d, cough 7 d). One case of
melioidosis pneumonia was detected by rapid test and confirmed by culture. Respiratory viruses were detected
in 16% (95% CI 12 to 21) of patients.
Conclusions: TB was very common in this population, suggesting that microscopy and GeneXpert MTB/RIF on
all sputum samples should be routinely included in diagnostic algorithms for fever and cough. Melioidosis was
uncommon in this population.
Keywords: Burkholderia pseudomallei, influenza, melioidosis, Myanmar, respiratory infection, tuberculosis
Introduction
Lower respiratory tract infections (LRTIs) were identified as
the leading infectious cause of death worldwide and the fifth
overall biggest killer in the 2015 Global Burden of Disease study.1
Conventional empirical therapy covering common community-
acquired bacterial pathogens is widely used in healthcare
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settings for suspected bacterial LRTIs. Understanding the local
prevalence of pathogens not susceptible to first-line empiri-
cal treatment is important for structuring population-specific
syndromic treatment guidelines.
Melioidosis was first discovered in Yangon (formerly Ran-
goon), Myanmar in 1911.2,3 It is now an emerging tropical
infection causing an estimated 165000 cases and 89000
deaths worldwide each year, exceeding many recognised
neglected tropical diseases, but it is greatly underdiagnosed.4
Pneumonia, secondary to either Burkholderia pseudomallei
inhalation or bacteraemic spread to the lung, is the most com-
mon presentation (51%).5 Annually the majority of reported
cases present in the rainy season (75% in Thailand) and up
to 80% of patients have at least one recognised risk factor,
including diabetes, alcohol dependence, glucocorticoid therapy,
chronic obstructive pulmonary disease, chronic renal disease
and cancer.6 Human immunodeficiency virus (HIV) infection
does not appear to increase the risk of melioidosis.7 Recent
soil sampling surveys have demonstrated the presence of B.
pseudomallei in central Myanmar, including Yangon,8,9 yet
there have been few published clinical cases in Myanmar since
1942.10,11 Difficulties diagnosing B. pseudomallei in resource-
poor endemic regions include lack of physician awareness of
the disease, clinical and radiological mimicry of other bacterial
infections, especially tuberculosis (TB),12 and limited access
to specialist laboratory facilities and expertise required for
diagnosis.11 Development of B. pseudomallei rapid tests could
expedite diagnosis and facilitate identifying communities where
melioidosis is currently an undescribed source of LRTI and
sepsis.
Myanmar is classified as a high-burden country for TB. Accord-
ing to the Global Tuberculosis Report 2020, in 2019 the inci-
dence of TB was 322/100000 population (uncertainty interval
212–454), the HIV prevalence among TB incident cases was
7.8% and the mortality incidence in HIV-uninfected and HIV-
infected individuals with TB was 36 (95% confidence interval [CI]
21 to 54) and 5.8 (95% CI 3.8 to 8.1), respectively. The esti-
mated percentage with multidrug-resistant (MDR) or rifampicin-
resistant TB among new cases was 4.9% (95% CI 4.7 to 5.1)
and among previously treated cases was 18% (95% CI 17
to 19).13
The primary aims of this study were to identify the proportion
of cases of LRTI caused by B. pseudomallei during the wet season
among adults attending outpatient clinics in Yangon and to eval-
uate the performance of a new rapid test, the Active Melioidosis
Detect Lateral Flow Assay (AMD-LFA; InBios, Seattle, WA, USA) on
sputum compared with culture (the gold standard). A secondary
objective was to identify leading alternative causes of LRTI that
would not be effectively treated by the usual empirical treatment
(oral amoxicillin)14 for LRTI in this population (i.e. TB and respira-
tory viruses).
Methods
Study area and population
This was a prospective observational study of patients attending
two outpatient clinics in Hlaingtharyar and Shwepyithar town-
ships, both large, crowded slums of Yangon, built on paddy fields,
with an estimated combined population of 1.3 million. Inhabi-
tants of these townships are generally poor, working in factories
or construction and to a lesser extent in farming. Unemployment
rates are high.
Medical Action Myanmar (MAM), a medical aid organisation,
runs clinics providing free healthcare in these townships 7 d a
week. These clinics provide general healthcare and specialist ser-
vices in HIV management. Chest infections are among the most
common presentations in adults at the clinic. Risk factors for both
TB and melioidosis (e.g. diabetes, alcohol abuse15,16 and renal
impairment17) are common in the region. The inclusion criteria
were consenting patients≥18 y of age reporting fever or having a
measured axillary temperature ≥37.5°C and a productive cough.
Patients unable to provide sputum specimens were excluded.
Data collected included demographic variables and self-
reported or previously documented risk factors (age, gender,
occupation, smoking history, diabetes status, alcohol depen-
dence [defined as the need to imbibe alcohol daily to suppress
physical symptoms of withdrawal], smoking and betel chewing
status, chronic lung disease, renal disease, drug history including
current steroid use, HIV status, record of any recent injury, near
drowning and occupational contact with soil) and symptoms
(reported fever, productive cough, haemoptysis, rigors, weight
loss, night sweats, shortness of breath and chest pain). Vital signs,
weight and physical examination findings were recorded on case
report forms. Patients were managed in accordance with the
current clinic guidelines.14 Empirical treatment with amoxicillin
or azithromycin was given to patients suspected of having bac-




Specimens were collected for acid-fast bacilli (AFB) microscopy,
GeneXpert MTB/RIF (Mycobacterium tuberculosis/resistance to
rifampicin; Cepheid, Sunnyvale, CA, USA), AMD-LFA rapid diagnos-
tic test (InBios) and selective B. pseudomallei culture (MacConkey
and Ashdown agar and selective enrichment broth). Ashdown
plates were incubated for 4 d. Enrichment broths were incubated
for 48 h at 37°C then subcultured on Ashdown agar for 4 d. Gram
stain for morphology of bacteria, API 20NE (bioMérieux, Marcy-
l’Étoile, France) and latex agglutination were used to confirm the
identity of B. pseudomallei.18 Positive isolates were sent to the
Menzies School of Health Research, Darwin, NT, Australia for con-
firmation of identity by specific polymerase chain reaction (PCR)
and whole genome sequencing (WGS).
Nasopharyngeal swabs
Specimens were frozen at−80°C and underwent respiratory virus
real-time PCR assays for detection of respiratory syncytial virus
(RSV), influenza A (including H1N1 typing) and influenza B at the
Shoklo Malaria Research Unit in Bangkok, Thailand.
Blood
Patients had blood tests for renal function (creatinine and urea),
full blood count (haemoglobin, platelets, white cell count), ran-
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cultures were taken from patients who were identified as sep-
tic with a quick sepsis-related organ failure assessment (qSOFA)
score ≥2 and sent to the National Health Laboratory, Yangon,
where they underwent automated blood culture with identifica-
tion and antibiotic susceptibility testing by VITEK 2 (bioMérieux).
Imaging
Chest radiographswere carried out by local radiology services and
the reports were documented and plain films were reviewed by
the clinicians to guide management.
Sample size calculation and statistical analysis
The formula used to calculate the sample size was
samplesizerequired = [(1.962) ∗ prevalence
∗ (1− prevalence)]/(precision2).
We considered what prevalence of melioidosis would be
required to encourage the introduction of a diagnostic test as
routine and we estimated that a sample size of 283 patients,
assuming a target population prevalence of B. pseudomallei of
10%, would provide precision of 3.5% with 95% confidence. This
number was rounded up to 300.
For comparisons of continuous variables between TB-positive
and TB-negative patients, two-sample Wilcoxon rank sum
(Mann–Whitney) tests were used. The 95% CIs for prevalences
were calculated using exact binomial (Clopper–Pearson) CIs. Sta-
tistical analyses were performed using Stata 14.2 (StataCorp, Col-
lege Station, TX, USA).
Results
The study took place between 9 July 2018 and 4 April 2019. The
baseline characteristics of the 299 patientsmeeting the inclusion
criteria are presented in Table 1. A total of 67% of study sub-
jects were male, the median age was 42 y (25th–75th percentile
25–50) and the median body mass index was 18.8 (25th–75th
percentile 17.3–21.8).
In the month prior to presentation, 34% (103/298) had spent
time in paddy fields, 3.0% (9/298) reported near-drowning expe-
riences and 14% (43/298) had had skin-breaching injuries. Other
factors known to be associated with melioidosis were alcohol
dependence in 17% (49/290) and current steroid use in 8.3%
(24/290). At presentation 4.8% (14/290) of patients had a known
diagnosis of diabetes and one new diagnosis was made dur-
ing the study. Prior to presentation, 18% (55/298) of patients
had already taken antibiotics, either obtained over the counter
or in other health centres (amoxicillin 12, co-amoxiclav 11,
flucloxacillin 1, azithromycin 1, ciprofloxacin 1, metronidazole 1,
cefixime 1, unknown 27).
Chest radiographs were abnormal in 73% (166/226) of
patients. Local radiologist–reported radiographs were 81% sen-
sitive and 79% specific for the detection of TB, with an 89% neg-
ative predictive value. Four patients with films locally reported as
Table 1. Clinical and demographic factors of the study population
Demographic factors (N=299) Values
Age (years) 42 (29–50)
Male, n (%) 200 (67)
Weight (kg) 48 (43–56)
Height (cm)a 160 (152–165)
Occupation (N=299), n (%)
Farmer 25 (8.4)
Manual worker 69 (23)
Housewife 29 (9.7)
Student 3 (1)




Fever duration (days)a 7 (3–18)
Productive cough duration (days)a 10 (5–30)
Weight loss, n (%) 161 (54)
Night sweats, n (%) 136 (46)
Chest pain, n (%) 146 (49)
Difficulty breathinga, n (%) 164 (55)
Rigorsa, n (%) 72 (24)
Myalgia, n (%) 186 (62)
Lethargya, n (%) 193 (65)
Concurrent medical issues (N=290), n (%)
Diabetes mellitus 14 (4.8)
HIV 10 (3.4)
Chronic lung disease 12 (4.1)
Chronic kidney disease 5 (1.7)
Cancer 4 (1.4)
Previous TBb 63 (21)
Social history (N=299), n (%)
Alcohol dependence 49 (17)
Betel chewer 151 (52)
Smoker or ex-smoker 127 (44)
Steroid use 24 (8.3)
Intravenous drug user 3 (1)
Medication (N=299), n (%)
Prior antibiotic treatment for this infection 55 (18)
Prior treatment with traditional medicine 32 (11)
Observations (N=299)
Axillary temperature (°C)a 37.0 (36.5–37.7)
Respiratory rate (breaths/min)a 20 (18–20)
Oxygen saturation (% room air) 97 (96–98)
Heart rate (beats/min) 92 (84–108)
Systolic blood pressure(mmHg)a 110 (100–120)
Investigations (N=299)
Haemoglobin (g/dl) 13.0 (11.7–14.3)
White cell count (×109/L) 9.8 (7.9–12.6)
Creatinine (mg/dL)a 1.00 (0.85–1.10)
CRP (mg/L)a 29 (9–75)
Data are presented asmedian (25th–75th percentile) unless stated
otherwise.
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having ‘no abnormalities detected’ tested positive on laboratory
tests for M. tuberculosis; one was HIV positive.
B. pseudomallei was detected in one patient by AMD-LFA and
culture (see Box 1). Specific PCR and WGS confirmed this was a B.
pseudomallei strain of a novel multilocus sequence typing type
(ST 1765) (https://pubmlst.org/bpseudomallei/).10 Susceptibility
testing of the isolate confirmed that it was resistant to gentam-
icin and colistin and susceptible to co-amoxiclav, co-trimoxazole,
ceftazidime and meropenem.
Box 1. Confirmed melioidosis case
A 38-year-old presented in rainy season with a 2-week history of
cough, fever, weight loss and lethargy. He was a manual worker
with regular exposure to paddy fields in the previous month. He
was a betel chewer and cigarette smoker, with no previous med-
ical history. On examination his temperature was 37.0°C, respi-
ratory rate 29 breaths/min, oxygen saturation 92% on room air,
heart rate 92 beats/min and blood pressure 120/80 mmHg. He
had already sought medical advice the previous week elsewhere
and had not responded to a short course of co-amoxiclav and
cefixime. On examination he was expectorating yellow sputum
with no abnormal chest findings or lymphadenopathy. His investi-
gations showed a random blood sugar of 131mg/dL, haemoglobin
12 g/dL, platelets 560, Urea 9 mg/dL and CRP 44 mg/L. His chest
radiographs showed a left-sided large lung abscess in the middle
zone. Negative results included HIV, sputum AFB and GeneXpert. B.
pseudomallei grew on Ashdown agar plates. He was transferred to
a local hospital where he was treated with 2 weeks of intravenous
ceftazidime 2 g every 8 h. He was subsequently followed up in clinic
and switched to co-trimoxazole 960 mg twice a day for 12 weeks.
On completion of therapy he had clinically recovered and a repeat
chest radiograph confirmed complete resolution of infection.
Evidence of TB was found in 32% of the study population
(95% CI 26 to 37). Seventy patients were positive by both
microscopy and GeneXpert MTB/RIF, 20 by GeneXpert MTB/RIF
alone and 5 bymicroscopy alone. Rifampicin resistancewas iden-
tified in nine of these cases.
Figure 1 shows the presence and duration of cardinal symp-
toms of TB (fever, productive cough, weight loss and night
sweats) and CRP at presentation in patients with and without TB.
Previous treatment for TB was reported in 21% (63/298). Symp-
tom duration was longer in TB-positive versus negative patients.
The median fever duration was 6 d (25th–75th percentile 3–10)
in non-TB patients and 15 d (25th–75th percentile 5–30) in TB
patients (p<0.0001) and productive cough had been present for
a median of 7 d (25th–75th percentile 4–14) in non-TB patients
and 30 d (25th–75th percentile 10–30) in TB patients (p<0.0001).
More than a quarter of patients (29%) reported known contact
with at least one relative or friend with TB. Themedian CRP of the
non-TB patients was 18 mg/L (25th–75th percentile 8–43) com-
pared with 65 mg/L (25th–75th percentile 35–128) in TB patients
Table 2. Potential pathogens identified from sputum or nasopha-
ryngeal swabs
Bacterial culture (non-mycobacterial) (N=299) n % 95% CI
Burkholderia pseudomallei 1 0.3 0 to 18
Burkholderia cepaciaa 1 0.3 0 to 18
TB (sputum smear and/or GeneXpert MTB/RIF positive; N=298)
TB 95 32 26 to 37
Rifampicin-resistant TB 9 3 1.6 to 5.6
Viruses (N=271)
Influenza A (all) 14 5.2 3.1 to 8.5
Influenza A (H1N1) 0 0 0 to 0
Influenza B 18 6.6 4.2 to 10
RSV 12 4.4 2.6 to 7.6
No pathogen detected 88 29 24 to 35
aLikely to represent colonisation.
(p<0.0001). Among the diabetic patients, 40% (6/15) presenting
with fever and cough tested positive for TB.
Using the respiratory virus real-time PCR assays, influenza
A was detected in 5.2% (95% CI 3.1 to 8.5) of nasopharyn-
geal swabs, influenza B in 6.6% (95% CI 4.2 to 10) and RSV in
4.4% (95% CI 2.6 to 7.6) (Table 2). Figure 2 shows viral diag-
noses were made predominantly in the wet season months of
July–October.
A potential bacterial or viral pathogen was detected in 46%
(95% CI 41 to 52) of cases (Table 2). Three patients had TB and
virus co-infection (one influenza A, one influenza B and one RSV).
Blood cultures were sent in two patients but were sterile.
At presentation, 3.4% (10/290) of patients had known HIV
infection and 19 (6.6%) people refused point-of-care HIV inves-
tigation at pre-test counselling. During the study, 19 (6.5%) new
cases of HIV infection were diagnosed. TB co-infection was diag-
nosed in 9 (31%) HIV-positive patients.
Discussion
Although this study was originally designed to investigate the
prevalence of melioidosis in patients presenting with LRTIs in
the MAM clinics, it has confirmed the importance of M. tuber-
culosis (32%) as a leading cause of fever and productive cough
in this population. Myanmar is among the 30 countries world-
wide with the highest burden of TB.13 Results from the 2018
national TB prevalence survey for the Yangon region found 108
of 3325 (3.2%) eligible adult participants tested had bacteriolog-
ically confirmed active TB, a prevalence which is 10-fold lower
than in this study.19 In the same survey, 4/108 (3.7%) individu-
als in Yangon were diagnosed with rifampicin-resistant TB, which
is highly suggestive of MDR-TB. In 2016, 54% of 2544 MDR-TB
cases started on second-line drugs nationally were in Yangon. In
2019 the estimated percentage of new cases nationally withMDR
or rifampicin-resistant TB was 4.9% (95% CI 4.7 to 5.1) and HIV
prevalence among TB-incident cases in Myanmar was 7.8%.13
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Figure 1. Comparison of symptom duration and CRP in patients with and without TB. (A) Fever duration was amedian of 15 d in TB patients compared
with 6 d in non-TB patients (p<0.0001). (B) Productive cough duration was 30 d in TB patients versus 7 d in non-TB patients (p<0.0001). (C) Weight
loss. (D) Night sweats. (E) Serum CRP (mg/L) measurements. Dots denote each patient, boxes denote 25th, 50th and 75th percentiles. Note that days
and CRP are presented on a log scale and for panels (C) and (D), zero values are displayed at 0.5 for clarity.
diagnosed with TB in our study and 9 (13%) patients were co-
infected with HIV. Around 17% (49/290) of patients reported
alcohol dependence. In a published survey between 2013 and
2014 of 1486 adults residing in urban and rural areas of the
Yangon region, age-standardised prevalence of heavy drinking
(defined as >40 g alcohol/d for men and >20 g for women) was
<5%.20 The catchment area served by the study clinics is home
to one of the most deprived populations in Myanmar, many of
whommoved to Yangon from the Delta region after Cyclone Nar-
gis in 2008. People are living in poverty in overcrowded condi-
tions. It is probable that rates of TB transmission are particu-
larly high in this area, which warrants further investigation. In
addition, 55 (18%) patients presented having already taken a
course of antibiotics, which is very common in Southeast Asian
countries where antibiotics are readily available over the counter.
Hence only those not responding to this initial empirical treat-
ment would continue to seek medical advice and are more likely
to have a more complex infection.
The high proportion of TB diagnosed in this study, and the
greater ascertainment withmolecular as opposed tomicroscopic
testing, suggests that screening all patients with a productive
cough and fever with routine GeneXpert MTB/RIF testing should
be considered in local diagnostic protocols.
TB was presumed to be the diagnosis in five patients (age
range 19–53 y, median 39 y) who were microscopy posi-
tive and GeneXpert MTB/RIF negative, although non-tuberculous
mycobacterial (NTM) infection is an alternative explanation, as
discussed by Phyu et al.21
Baseline CRP was significantly higher in TB patients than non-
TB patients (p<0.0001) (see Figure 1), but whether this supports
introduction of routine CRP testing as a point-of-care screening
or diagnostic tool for differentiating TB in this setting requires a
better-powered study. The value of CRP as a marker of mycobac-
terial infection in European patients was dependent on ethnicity,
the species of mycobacterium and the site of disease.22 In view
of the high proportion of this population found to have TB, active
case finding may be better than passive case detection in con-
trolling the rates of infection, as demonstrated by Marks et al.23
in Vietnam.
The proportion of HIV-positive patients with TB (31% [9/29])
was comparable to that in HIV-negative patients (32% [86/270]).
The diagnosis of 18 new HIV cases during this study empha-
sises the importance of opportunistic testing in patients present-
ing to healthcare centres with infections in areas of high preva-
lence. The high proportion of new HIV infections is not represen-
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Figure 2. Proportion of patients with respiratory virus (influenza A, influenza B and RSV) positive by month in 2018–2019 (n=299). Circles denote
observed proportions, capped vertical bars denote the 95% CIs. Number of patients contributing to each month are the numbers over each data
point.
HIV specialist services andmay consequently attract a higher-risk
population.
Studies in Thailand and Cambodia have identified melioidosis
as an important TB mimic that should be considered in patients
testing negative for TB but presenting with similar respiratory
infection.12,24 B. pseudomallei remains an important differen-
tial for clinicians to consider in patients in melioidosis-endemic
countries. This study confirms that melioidosis still exists in Yan-
gon and should be considered as a cause of LRTIs, although it
was uncommon in this study population. The AMD-LFA, which
detects B. pseudomallei 6-deoxyheptan capsular polysaccha-
ride antigen, has been specifically developed for resource-poor,
melioidosis-endemic settings where B. pseudomallei culture is
frequently not available.25 It has been evaluated on blood culture
broths in Cambodia and Laos26 and directly on clinical samples in
Australia,27 Laos,28,29 Thailand30 and India.31 Shaw et al.31
demonstrated an overall sensitivity of 86% (CI 75 to 93) and
specificity of 94% (CI 88 to 97) with a positive predictive value
of 86% (CI 76 to 92) compared with culture on multiple types
of specimens. The estimated bacillary load of B. pseudomallei
in sputum and pus is 1.1×105 CFU/mL, higher than other clini-
cal samples (e.g. blood), making them promising specimen types
for AMD-LFA testing.26,27,32 In the respiratory samples (n=45)
tested by Shaw et al.,31 the AMD-LFA detected all five culture-
positive samples. In Laos, a study by Woods et al.29 found 100%
specificity and 33% sensitivity on sputum (n=20), while a further
study in Laos28 demonstrated a specificity of 100% and sensitiv-
ity of 80% in sputum specimens (n=28). Reduced time to diag-
nosis with this novel test has previously been demonstrated in
Laos.28 In our patient, the diagnosis of melioidosis was expe-
dited by the rapid diagnostic test. The AMD-LFAwas accurate and
fast, providing a positive result within 15 min of testing the spu-
tum, 1 week before the diagnosis was confirmed by culture. This
enabled rapid commencement of appropriate treatment (cef-
tazidime) in a patient who would otherwise have been empir-
ically commenced on inappropriate antibiotics, with potentially
fatal consequences. At this stage, the likely market price of the
AMD-LFA is unknown and so we cannot comment on the costs
and benefits of its routine use in this population, although tar-
geted use in specific risk groups and patients with severe pneu-
monia and sepsis is likely to be most cost effective.
Contributory factors to the low prevalence of B. pseudomallei–
associated LRTIs in this population include logistical delays lead-
ing to recruitment to the study starting 2 months into the rainy
season. A majority of the patients were recruited in the lower-
risk risk dry months. More acutely unwell patients may have pre-
sented directly to hospital rather than to community outpatient
clinics.
Diabetes was a risk factor for TB in this study, with 40% (6/15)
of diabetics presenting with a productive cough testing posi-
tive. Diabetes mellitus is among the top 10 causes of death in
Myanmar and is thought to be largely undiagnosed.33 Immuno-
suppression caused by glycaemic dysregulation predisposes the
patient to a wide range of infections. A systematic review of
2.3 million patients with active TB globally estimated a pooled
international prevalence of diabetes of 15.3%. The regional dia-
betes prevalence in Southeast Asia is 19%.34 This association
supports screening patients with TB for diabetes at diagnosis and
vice versa. Diabetes is also the leading risk factor for melioidosis,
increasing the risk of the infection 12-fold.35
Real-time respiratory virus PCR testing showed seasonal
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cases were influenza B, which developed after an initial wave of
influenza A, and was followed by RSV infections. This is in keeping
with published Myanmar surveillance records.36
Conclusions
This study demonstrates an unexpectedly high proportion of
infections that would not be expected to respond to the usual
empirical antibiotic treatment regimens, particularly TB, in this
study population in Yangon. Screening all patients with a produc-
tive cough and fever with chest radiographs, AFBmicroscopy and,
where affordable, routine GeneXpert MTB/RIF testing should be
considered in local diagnostic protocols. In this population, high
CRP was associated with TB diagnosis, requiring further investiga-
tion to establish its value as an additional diagnostic or screen-
ing tool. A high proportion of patients with diabetes and respira-
tory symptoms had TB (40%), emphasising the particular need
for active screening in this patient group. Given 21% of patients
in this study had had previous TB and thus are at increased risk
of chronic lung damage, future treatment guidelines should also
consider incorporating bronchiectasis management. The AMD-
LFA identified a single (later culture confirmed) case of melioido-
sis and significantly reduced the time to diagnosis. It is a poten-
tially useful test in patients at high risk of melioidosis, although
the cost-effectiveness of instituting such a test routinely will
depend on the local prevalence of melioidosis. Understanding
the local burden of infections that are not susceptible to first-
line empirical treatment in adults is essential for structuring syn-
dromic pathways tailored to the population and may help to
reduce inappropriate use of antimicrobials in the context of grow-
ing resistance.
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